What is the clinical management protocol if a patient develops transient papules or mild oedema at the sub-mucosal injection sites
Breakdown Timeline No protocol Women’s Health Clinic FAQ What is the clinical management protocol if a patient develops transient papules or mild ooedema at the sub-mucosal…
How do clinicians screen for active vulvovaginal infections (yeast, BV, STIs) before proceeding with intimate polynucleotide injections
Inflammation Pain pathways Specialist review Women’s Health Clinic FAQ How do clinicians screen for active vulvovaginal infections (yeast, BV, STIs) before proceeding with intimate polynucleotide injections…
What is the safety profile of polynucleotides when injected into tissue containing previously placed synthetic pelvic mesh or slings
Matrix biology Barrier function Realistic claims Women’s Health Clinic FAQ What is the safety profile of polynucleotides when injected into tissue containing previously placed synthetic pelvic…
Can polynucleotides be safely administered to patients taking systemic immunosuppressive or anti-rheumatic biologic therapies
Inflammation Pain pathways Specialist review Women’s Health Clinic FAQ Can polynucleotides be safely administered to patients taking systemic immunosuppressive or anti-rheumatic biologic therapies Inflammation and nerve-density…
What precautions are necessary when administering polynucleotides to patients with active autoimmune diseases like systemic lupus erythematosus
Inflammation Pain pathways Specialist review Women’s Health Clinic FAQ What precautions are necessary when administering polynucleotides to patients with active autoimmune diseases like systemic lupus erythematosus…
What is the risk of localised micro-haematoma or purpura formation when injecting vascularly fragile atrophic mucosa with polynucleotides
Oxidative stress Microvascular Cautious biology Women’s Health Clinic FAQ What is the risk of localised micro-haematoma or purpura formation when injecting vascularly fragile atrophic mucosa with…
How do regulatory bodies (e.g., UKCA, CE mark, FDA) classify polynucleotide medical devices versus cell-based biological drugs
Quality control Source material Traceability Women’s Health Clinic FAQ How do regulatory bodies (e.g., UKCA, CE mark, FDA) classify polynucleotide medical devices versus cell-based biological drugs…
What is the protocol for managing an accidental intravascular injection into the anterior vaginal venous plexus during polynucleotide therapy
Oxidative stress Microvascular Cautious biology Women’s Health Clinic FAQ What is the protocol for managing an accidental intravascular injection into the anterior vaginal venous plexus during…
Are there any known drug interactions between localised polynucleotide gels and concurrent topical antifungals or steroids
Quality control Source material Traceability Women’s Health Clinic FAQ Are there any known drug interactions between localised polynucleotide gels and concurrent topical antifungals or steroids Source…
What is the safety timeline for administering polynucleotide injections in patients who have recently completed pelvic chemotherapy
Oxidative stress Microvascular Cautious biology Women’s Health Clinic FAQ What is the safety timeline for administering polynucleotide injections in patients who have recently completed pelvic chemotherapy…
Still not sure where to start?
Browse the wider treatment pages or book a free consultation so we can help you find the most relevant next step.
